ArticleBMC pediatrics2026
Neonate screening for glucose-6-phosphate dehydrogenase deficiency in South Kivu, eastern Democratic Republic of Congo.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymatic disorder and an important risk factor for severe neonatal hyperbilirubinemia. In the Democratic Republic of the Congo (DRC), neonatal data on G6PD deficiency remain limited. This study aimed to screen for G6PD deficiency among neonates in South Kivu, eastern DRC.
methodsA cross-sectional hospital-based study was conducted from April to August 2022 in three maternity wards in South Kivu. Live-born neonates whose parents provided informed consent were screened within one hour of birth. G6PD activity was measured on dried blood spots using the fluorescent spot test. G6PD deficiency was defined as enzyme activity < 30% of normal activity. Prevalence estimates with 95% confidence intervals (CI) were calculated, and associations were assessed using bivariate analysis.
resultsAmong 1,188 neonates screened, four had doubtful results. Among the 1,184 neonates with valid results, 73 were G6PD deficient, corresponding to an overall prevalence of 6.2% (95% CI: 4.9-7.7). Prevalence ranged from 2.9% to 7.7% across study sites, with no significant difference between maternity wards (p = 0.11). G6PD deficiency was more frequent among males than females (10.1% vs. 1.5%), and male sex was significantly associated with deficiency (odds ratio 7.49; 95% CI: 3.56-15.77).
conclusionNeonatal G6PD deficiency is relatively common in South Kivu and exceeds thresholds commonly proposed for targeted neonatal screening. These findings support consideration of neonatal G6PD screening strategies in the DRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.